Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review

References

• Tang ER, Schreiner AM, Pua BB. Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS). J Thorac Dis. 2014;6(Suppl 5):S489–501.
   PubMedGoogle Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
   PubMed Web of Science ®Google Scholar
• Cha YJ, Shim HS. Biology of invasive mucinous adenocarcinoma of the lung. Transl Lung Cancer Res. 2017;6(5):508–512. doi:10.21037/tlcr.2017.06.10
   PubMed Web of Science ®Google Scholar
• Shim HS, Kenudson M, Zheng Z, et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. J Thor Oncol. 2015;10(8):1156–1162. doi:10.1097/JTO.0000000000000579
   PubMed Web of Science ®Google Scholar
• Tian P, Liu Y, Zeng H, et al. Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. J Cancer Res Clin Oncol. 2020;146(4):935–944. doi:10.1007/s00432-019-03116-6
   PubMed Web of Science ®Google Scholar
• Franco R, Rocco G, Marino FZ, et al. Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment? Expert Rev Anticancer Ther. 2013;13(4):407–420. doi:10.1586/era.13.18
   PubMed Web of Science ®Google Scholar
• Sabir SR, Yeoh S, Jackson G, Bayliss R. EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers. 2017;9:9. doi:10.3390/cancers9090118
   PubMed Web of Science ®Google Scholar
• Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a Phase II global study. J Clin Oncol. 2016;34(7):661–668. doi:10.1200/JCO.2015.63.9443
   PubMed Web of Science ®Google Scholar
• Tamura T, Kiura K, Seto T, et al. Three-year follow-up of an alectinib Phase I/II study in ALK-positive non-small-cell lung cancer: AF-001JP. J Clin Oncol. 2017;35(14):1515–1521. doi:10.1200/JCO.2016.70.5749
   PubMed Web of Science ®Google Scholar
• Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, Phase 2 trial. Lancet Oncol. 2016;17(2):234–242. doi:10.1016/S1470-2045(15)00488-X
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Shaw AT, Govindan R, et al. Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J Clin Oncol. 2016;34(34):4079–4085. doi:10.1200/JCO.2016.68.4639
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines insights: non-small cell lung cancer, Version 5.2018. J Natl Comp Cancer Net. 2018;16(7):807–821. doi:10.6004/jnccn.2018.0062
   PubMed Web of Science ®Google Scholar
• Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated alk-positive advanced non-small cell lung cancer in the global Phase III ALEX study. J Thor Oncol. 2019;14(7):1233–1243. doi:10.1016/j.jtho.2019.03.007
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018;29(11):2214–2222. doi:10.1093/annonc/mdy405
   PubMed Web of Science ®Google Scholar
• Montemurro F, Nuzzolese I, Ponzone R. Neoadjuvant or adjuvant chemotherapy in early breast cancer? Expert Opin Pharmacother. 2020;21(9):1071–1082. doi:10.1080/14656566.2020.1746273
   PubMed Web of Science ®Google Scholar
• Group NM. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet (London, England). 2014;383(9928):1561–1571. doi:10.1016/S0140-6736(13)62159-5
   PubMed Web of Science ®Google Scholar
• Leonetti A, Minari R, Boni L, et al. Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable stage III ALK-positive NSCLC: ALNEO trial. Clin Lung Cancer. 2021;22(5):473–477.
   PubMed Web of Science ®Google Scholar
• Zhang C, Yan LX, Jiang BY, Wu YL, Zhong WZ. Feasibility and safety of neoadjuvant alectinib in a patient with ALK-positive locally advanced NSCLC. J Thor Oncol. 2020;15(6):e95–e99. doi:10.1016/j.jtho.2019.12.133
   PubMed Web of Science ®Google Scholar
• Cai D, Li H, Wang R, et al. Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma. Onco Targets Ther. 2014;7:2127–2132.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M. Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings. Onco Targets Ther. 2017;10:153–163. doi:10.2147/OTT.S121059
   PubMed Web of Science ®Google Scholar
• Sun F, Wang P, Zheng Y, et al. Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma. Oncol Lett. 2018;15(1):489–494.
   PubMed Web of Science ®Google Scholar
• Kim H, Jang SJ, Chung DH, et al. A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype. PLoS One. 2013;8(10):e76999. doi:10.1371/journal.pone.0076999
   PubMed Web of Science ®Google Scholar
• Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11–23. doi:10.1038/nrc2291
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. doi:10.1038/nature05945
   PubMed Web of Science ®Google Scholar
• Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer. 2013;13(10):685–700. doi:10.1038/nrc3580
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253. doi:10.1200/JCO.2009.22.6993
   PubMed Web of Science ®Google Scholar
• Possidente L, Landriscina M, Patitucci G, Borgia L, Lalinga V, Vita G. ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features. Med Oncol. 2017;34(5):76. doi:10.1007/s12032-017-0936-z
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–838. doi:10.1056/NEJMoa1704795
   PubMed Web of Science ®Google Scholar
• Nishio M, Nakagawa K, Mitsudomi T, et al. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2018;121:37–40. doi:10.1016/j.lungcan.2018.04.015
   PubMed Web of Science ®Google Scholar
• Fan J, Fong T, Xia Z, Zhang J, Luo P. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: a network meta-analysis. Cancer Med. 2018;7(10):4993–5005. doi:10.1002/cam4.1768
   PubMed Web of Science ®Google Scholar
• Kappers I, Klomp HM, Burgers JA, Van Zandwijk N, Haas RL, van Pel R. Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. J Clin Oncol. 2008;26(25):4205–4207. doi:10.1200/JCO.2008.16.3709
   PubMed Web of Science ®Google Scholar
• Takamochi K, Suzuki K, Sugimura H, et al. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer (Amsterdam, Netherlands). 2007;58(1):149–155. doi:10.1016/j.lungcan.2007.04.016
   PubMed Web of Science ®Google Scholar
• Imanishi N, Yoneda K, Taira A, et al. Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung. Surg Case Rep. 2018;4(1):19. doi:10.1186/s40792-018-0430-7
   PubMedGoogle Scholar
• Leonetti A, Minari R, Boni L, et al. Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable Stage III ALK-positive NSCLC: ALNEO trial. Clin Lung Cancer. 2021;22(5):473–477.
   PubMed Web of Science ®Google Scholar